For research use only. Not for therapeutic Use.
PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity[1].
| Catalog Number | I024722 |
| CAS Number | 1627710-30-8 |
| Synonyms | (2Z)-2-[[3-[(4-chlorophenyl)methoxy]phenyl]methylidene]-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazin-3-one |
| Molecular Formula | C20H17ClN2O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H17ClN2O2S/c21-16-7-5-14(6-8-16)13-25-17-4-1-3-15(11-17)12-18-19(24)23-9-2-10-26-20(23)22-18/h1,3-8,11-12H,2,9-10,13H2/b18-12- |
| InChIKey | XJBQRMOGMULGPP-PDGQHHTCSA-N |
| SMILES | C1CN2C(=O)C(=CC3=CC(=CC=C3)OCC4=CC=C(C=C4)Cl)N=C2SC1 |
| Reference | [1]. Kotańska M, et al. Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. Pharmaceuticals (Basel). 2021;14(3):270. |
